Email this morning:
Dear Shareholders,
2019 has been an amazing ride so far for NNRX. We have been extraordinarily busy due to the time of year and what this means in the world of hemp. We are very close to being able to release specifics to the market, but in the interim we wanted to give those following NNRX an update.
We will be announcing the NutraNomics executive team in the near future. We have been phenomenally fortunate to be able to secure some of the most seasoned administrative talents for NNRX in all of our market sectors. In future announcements, you will see mentions of the buildout of our Agricultural team who is tasked with the acquisition, analysis, and management of the farming and extraction aspects of NNRX global strategy. This team will cover both domestic and international production lead by an experienced leader with 35-years experience and supported by executives and directors with substantial, real-life experience in growing and extracting hemp.
While the Agricultural sector is encompassed in our BioMedical Division, there is some significant overlap with our Wholesale Materials Division lead by a genuine powerhouse experienced in not only driving sales and engagement but analyzing trends and capturing data required to help predict market demand. The isolate/distillate markets have made a predictable swing this year away from isolates and more towards full or broad-spectrum distillate to take advantage of the benefits of the whole plant. As with all products and extractions associated with NNRX, our products have less than .3% THC, making them federally legal (with zero psychoactive effect) under the existing and somewhat cloudy laws regarding CBD. We expect more clarity in the near future regarding how the FDA will address labeling and access to products with CBD and are poised to move quickly on the release.
Our Operations and Contract Services team has also filled out with new officers and directors leading the growth and expansion of the company. The Contract Service Division is responsible for the marketing and sales of NutraNomics created products, as well as other non-NNRX products that require a more robust marketing arm to drive sales through partnership and platform marketing.
Internally, NNRX has moved forward with some significant new product development. On deck for a complete redesign is our top seller, which is being reformulated to go from being absorbed through the digestive tract to a pre-digestive delivery. This new delivery system provides for an almost instantaneous delivery into the bloodstream to provide the most immediate results. The product will be ready within 12 weeks with new branding and packaging to reflect our newly invigorated approach to health.
Hand in hand with the reformulation, we have two other products ready to be branded and brought to market, including our first product with CBD in a nano-sized format and featuring mangosteen, another powerful anti-inflammatory component. The two-in-one product provides an unparalleled nutraceutical designed to hit all the expectations when looking for immediate delivery into the system. Also, on deck is a nano-sized Vitamin D supplement that will help anyone suffering from depleted levels.
NNRX has made some significant strides internationally. We are currently vetting several project opportunities – from the Caribbean to Africa to South America. In order to maximize NNRX ability to take advantage of both European finance opportunities and licensing for import and export of hemp into the EU, NutraNomics has opened a UK subsidiary, NUTRANOMICA UK LIMITED. In the near future, press releases regarding the specifics of this subsidiary and its operators will be disclosed. We will also be in a position to announce all farming and acreage, both domestically and internationally, that has been finalized at that time. Key metrics for disclosure includes full execution of all agreements, funding in place, and approval for release publicly of quotes and information by our partners. We know that information is desired and want nothing more than to disclose everything we are working on. To remain responsible to the market and our partners, we are following strict protocols with regards to release of information. We do expect that you will be very pleased with the information through the balance of this summer and 2019.
One of the last points to touch on is the announcement of strategic partnerships. We are in a position to announce some very potent partnerships in the near future. Some are just waiting on the final review of agreements, others are waiting on PR approval. Suffice it to say that when we are in a position to make an announcement, we will do it often and with gusto.
As always, we appreciate the dedication of our shareholders and the tenacity with which you pursue information and validation. While your enthusiasm is appreciated, it also presents a challenge. We are working diligently to get as much work done in this critical period. From the inside, this is the most time-consuming aspect of what we are working to accomplish. From the outside, it may look like there is not a lot going on. Still waters run deep, however. Rest assured that we are working daily to accomplish critical path tasks and goals. On the advice of counsel, we have opted to put off our Shareholders meeting until the end of the summer. In the interim, we will be posting regular press releases as they become vetted and meet our strict criteria for release.
Our goal is to provide transparency while remaining true to the covenants made to the markets and required by law. This is not always an easy aspect to straddle. During the first half of this year, we have poured all our efforts into our BioMedical and Wholesale Materials Divisions, turning now to a greater focus on Contract Services and Sales. We will be able to transition more time and effort into communications, but if they are sporadic, just know there is a good reason for it.
Thank you as always. We appreciate the opportunity to pursue a unique course in bringing highly effective nutraceutical products to market featuring cutting edge absorption and delivery science.
Sincerely,
Jonathan Bishop
CEO NutraNomics
OTC:NNRX
